8-K: NewAmsterdam Pharma Q3 Update: Obicetrapib Advances, Net Loss Widens

NewAmsterdam Pharma announced its third-quarter 2025 financial results and provided corporate updates, including EMA acceptance of obicetrapib applications and ongoing clinical trial progress.

Summary

• Reported a net loss of $72.0 million for the quarter ended September 30, 2025, compared to a net loss of $16.6 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities totaled $756.0 million as of September 30, 2025, down from $834.2 million at December 31, 2024.
• The European Medicines Agency (EMA) accepted Marketing Authorization Applications (MAAs) for obicetrapib monotherapy and its fixed-dose combination (FDC) with ezetimibe for review.
• Pooled efficacy and safety data from the pivotal Phase 3 BROADWAY and BROOKLYN trials were published in the Journal of the American College of Cardiology, highlighting obicetrapib's performance.
• A pre-specified Alzheimer's substudy from the BROADWAY trial was published in the Journal of Prevention of Alzheimer's Disease, showing obicetrapib reduced p-tau217 levels by 20.5% in ApoE4/E4 carriers over 12 months.
• The PREVAIL Phase 3 cardiovascular outcomes trial (CVOT) completed enrollment of over 9,500 patients in April 2024.
• The REMBRANDT Phase 3 imaging trial, evaluating the FDC of obicetrapib plus ezetimibe on coronary plaque, is ongoing and expected to enroll 300 patients.
• The RUBENS Phase 3 clinical trial, evaluating obicetrapib in combination with ezetimibe for type 2 diabetes or metabolic syndrome patients, is expected to initiate in the fourth quarter of 2025.

Sentiment

Score: 6

Explanation: While financial results show a significant increase in net loss and decrease in revenue, the underlying cause is largely the absence of a one-time milestone payment from the prior year, rather than a fundamental deterioration of core operations. The company demonstrates strong clinical progress with EMA acceptance, positive trial data publications, and ongoing advanced-stage trials, which are crucial for future value creation in a biopharmaceutical company. The cash position remains robust, supporting future operations and potential launch.

Positives

• EMA accepted Marketing Authorization Applications for obicetrapib monotherapy and the fixed-dose combination with ezetimibe, a significant regulatory milestone for European market access.
• Positive pooled MACE analysis from BROADWAY and BROOKLYN trials published in the Journal of the American College of Cardiology, showing a 21% observed reduction in MACE favoring obicetrapib at 1-year (exploratory endpoint).
• Alzheimer's substudy data from BROADWAY published in the Journal of Prevention of Alzheimer's Disease, demonstrating a 20.5% reduction in p-tau217 levels in high-risk ApoE4/E4 carriers over 12 months.
• Strong cash, cash equivalents, and marketable securities position of $756.0 million as of September 30, 2025, providing funding to support potential US commercial launch.
• Completed enrollment of over 9,500 patients in the PREVAIL Phase 3 cardiovascular outcomes trial, a major step towards assessing MACE reduction.
• Expected initiation of the RUBENS Phase 3 trial in Q4 2025 expands the clinical pipeline into type 2 diabetes and metabolic syndrome.
• Robust intellectual property protection for obicetrapib's composition of matter extends until mid-2043.
• Obicetrapib demonstrated beneficial effects beyond LDL-C, including on ApoB, non-HDL-C, LDL-P, HDL-C, and markers of glycemic control, renal function, and Alzheimer's disease.

Negatives

• Net loss for Q3 2025 significantly increased to $72.0 million, compared to a net loss of $16.6 million for Q3 2024.
• Revenue decreased substantially to $0.3 million in Q3 2025 from $29.1 million in Q3 2024, primarily due to the absence of a $27.3 million clinical development milestone recognized in the prior year.
• Selling, General and Administrative (SG&A) expenses increased to $24.5 million in Q3 2025 from $18.4 million in Q3 2024, driven by higher personnel expenses and share-based compensation.
• A non-cash loss of $23.792 million was recorded in Q3 2025 due to changes in the fair value of derivative warrant liabilities.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Risks related to the approval of product candidates and the timing of expected regulatory and business milestones, including potential commercialization.
• Uncertainty whether topline, initial, or preliminary results from a particular clinical trial will be predictive of the final results of that trial.
• Uncertainty whether results of early clinical trials will be indicative of the results of later clinical trials, or whether projections regarding clinical outcomes will reflect actual results in future clinical trials or clinical use.
• Potential for varying interpretation of the results of clinical trials and analyses, including the Alzheimer's disease sub-study and potential drivers of observed MACE reduction.
• Impact of competitive product candidates on the company's business.
• Ability to obtain sufficient supply of materials for product candidates.
• Global economic and political conditions.
• Ability to negotiate and enter into definitive agreements on favorable terms, if at all.
• Risks and uncertainties relating to intellectual property and regulatory exclusivities.
• Ability to attract and retain qualified personnel.
• Ability to continue to source the raw materials for product candidates.

Future Outlook

The company expects to present additional data on obicetrapib's impact on LDL particles at the American Heart Association's Scientific Sessions in November 2025. It plans to initiate the RUBENS Phase 3 clinical trial in Q4 2025 and continues to advance its PREVAIL cardiovascular outcomes trial and REMBRANDT imaging trial. The PREVAIL trial could conclude as early as the end of 2026, but will continue until the target number of MACE events occur, likely extending beyond this point. The company is also building its global infrastructure to support the potential commercial launch of obicetrapib, if approved.

Management Comments

• "We remain acutely focused on our mission to deliver obicetrapib, as a novel, well-tolerated, and conveniently administered therapy for millions of patients with cardiometabolic disease who continue to struggle to reach their LDL-C goals."
• "In the third quarter, we achieved a significant regulatory milestone with the European Medicines Agency’s (EMA) acceptance for review of the marketing authorization applications (MAAs), by our partner Menarini, for both obicetrapib monotherapy and the fixed-dose combination (FDC) with ezetimibe."
• "These submissions, supported by data from our pivotal BROADWAY, BROOKLYN and TANDEM trials, represent an important step toward bringing obicetrapib to patients across Europe."
• "In parallel, we continue to advance our broader clinical development strategy, including PREVAIL, our ongoing cardiovascular outcomes trial (CVOT), and REMBRANDT, our Phase 3 imaging trial."
• "We are also making meaningful progress building our global infrastructure to support the potential launch of obicetrapib, if approved."

Industry Context

Cardiovascular disease remains the leading cause of death globally, with US age-adjusted mortality rates increasing by 9% from 2019-2022, reversing a decade of progress. Despite existing lipid-lowering therapies (LLTs), millions of patients, particularly those with ASCVD, do not achieve their LDL-C target goals, underscoring a significant clinical need for improved therapeutic regimens. The lipid-lowering market is experiencing growth, with non-statin and branded agents seeing high double-digit growth, and guidelines shifting towards more aggressive treatment. Obicetrapib, as an oral, once-daily, non-statin CETP inhibitor, aims to address this unmet need by offering significant LDL-C lowering and observed beneficial effects beyond LDL-C, including on Lp(a), LDL particles, and biomarkers for diabetes and Alzheimer's disease, positioning it for comprehensive risk management in a large and growing market.

Comparison to Industry Standards

• **Obicetrapib (monotherapy)**: Observed 35-40% LDL-C reduction, 34-56% Lp(a) lowering, well-tolerated, oral, once-daily. Exploratory MACE reduction of 21% at 1-year (BROADWAY + BROOKLYN pooled).
• **Obicetrapib + Ezetimibe (FDC)**: Observed 49-54% LDL-C reduction, 63% Lp(a) lowering, well-tolerated, oral, once-daily.
• **Ezetimibe**: Approved, oral, 15% LDL-C reduction, no MACE benefit, well-tolerated.
• **Nexletol (Bempedoic Acid)**: Approved, oral, 13% LDL-C reduction, 17% MACE benefit, but carries tendon rupture & gout warnings.
• **PCSK9i (Injectable)**: Approved, injectable, 25% LDL-C reduction, 17% MACE benefit, associated with injection site reactions.
• **MK-0616 (Oral PCSK9)**: Phase 3 ongoing, 50-59% LDL-C reduction (reduced to ~20% with food), oral peptide, requires 8-hour fast and 30-minute wait, SNAC technology previously observed to have tolerability concerns.
• **AZD0780 (Oral small molecule)**: Phase 2b, 35-51% LDL-C reduction, well-tolerated, but with reported SAEs and cases of AST/ALT > 5x ULN.
• **Prior CETP Inhibitors (Torcetrapib, Dalcetrapib, Evacetrapib, Anacetrapib)**: Obicetrapib demonstrates higher CETP inhibition (97% vs. 30-80%), greater LDL-C reduction (35-40% vs. 7-25%), no blood pressure increase (unlike Torcetrapib), and significant Lp(a) and ApoB lowering, addressing limitations of previous CETP inhibitors.

Stakeholder Impact

• **Shareholders**: Potential for long-term value creation through clinical advancements and regulatory approvals, but short-term financial performance (increased loss, decreased revenue) may cause concern. Dilution from warrant exercises and RSU vesting is noted in the equity statement.
• **Patients**: Potential for a new, well-tolerated, and effective oral therapy for cardiovascular disease and potentially Alzheimer's disease, addressing significant unmet needs.
• **Employees**: Continued growth and expansion of commercial and MSL functions, indicating job stability and growth opportunities.
• **Regulatory Authorities**: EMA acceptance of MAAs indicates progress towards market approval in Europe.
• **Partners (Menarini)**: Continued collaboration on regulatory submissions and commercialization in Europe.

Next Steps

• Present additional data at the American Heart Association's Scientific Sessions 2025 in November 2025, highlighting obicetrapib's impact on LDL particles.
• Initiate the RUBENS Phase 3 clinical trial in Q4 2025 to evaluate obicetrapib in combination with ezetimibe in patients with type 2 diabetes or metabolic syndrome.
• Continue the PREVAIL Phase 3 cardiovascular outcomes trial until the target number of MACE events occur, with the earliest conclusion expected at the end of 2026.
• Continue the REMBRANDT Phase 3 imaging trial to evaluate the effect of obicetrapib plus ezetimibe FDC on coronary plaque.
• Build global infrastructure to support the potential launch of obicetrapib, if approved.

Key Dates

Recommendation

The company reported a significantly wider net loss and a sharp decline in revenue for Q3 2025, primarily due to the absence of a one-time milestone payment from the prior year. While these financial metrics are negative, the core business, a late-stage biopharmaceutical company, is making substantial clinical and regulatory progress. The EMA's acceptance of marketing applications for obicetrapib, positive data publications (MACE, Alzheimer's biomarkers), and ongoing pivotal trials (PREVAIL, REMBRANDT, upcoming RUBENS) are strong indicators of future potential. The company maintains a robust cash position of $756.0 million, which is critical for funding its extensive clinical pipeline and potential commercial launch. Given the mixed financial results but strong clinical momentum and sufficient liquidity, a "Hold" recommendation is appropriate. Investors should monitor the progress of regulatory approvals and the outcomes of ongoing and upcoming clinical trials, particularly the PREVAIL CVOT, which will be a key determinant of long-term value.

Keywords

Obicetrapib, CETP inhibitor, LDL-C lowering, Cardiovascular disease, Alzheimer's disease biomarkers, EMA approval, Clinical trials, PREVAIL, REMBRANDT, RUBENS, Hypercholesterolemia, Dyslipidemia, Biopharmaceutical, Q3 2025 financial results, NAMS